TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Novavax's VLP Flu Vaccine Is A Game Changer To quote Tuesday’s Wall Street Journal, “Novavax is a winner.”That certainly seems to be the consensus after the company released big news on Monday. According to the Maryland based company, Phase II clinical trials of its seasonal influenza virus-like particle vaccine showed the vaccine was well tolerated and worked well against three types of seasonal flu, including H1N1.Complete Story » seekingalpha.com |
BioMed News Bytes: Dendreon, Chelsea, Cytori, Cephalon, OraSure, Genzyme, Lixte Mike Havrilla submits:On 4/28/09, Dendreon (DNDN) announced that its experimental cancer vaccine Provenge extended the life of patients with advanced prostate cancer by a median of 4.1 months, which is one month longer than the only other treatment option, Taxotere. On 9/24/09, DNDN announced plans to file an amendment to its existing BLA seeking FDA approval in mid-November for Provenge with a possible decision by the Agency likely to occur around mid-2010. The Company will have the manufacturing capacity to generate possible sales of $60-125 million during 2H10 until full capacity is achieved in late 2011. Complete Story » seekingalpha.com |
FDA Targets Food Package Labels The Food and Drug Administration said it will start cracking down on any logos and symbols on cereals, snacks and other food packages that may be misleading consumers on the products' heath benefits. online.wsj.com |
Jury Awards $28 Million in Hormone Suit A Pennsylvania state court awarded the punitive damages to a plaintiff who claimed her use of Pfizer's hormone-therapy drugs caused breast cancer; she was awarded $6.3 million in compensatory damages last week. online.wsj.com |
Biotech’s 2009 Stealth Small Cap Rally Michael Becker submits:On the heels of the Dow Jones Industrial Average (DJIA) logging its worst annual performance since 1931 and the NASDAQ Composite (COMP) having its worst year since inception in 1971, it may have seemed counter intuitive to provide a bullish outlook for the biotechnology industry in 2009. Nonetheless, at the start of the year we provided a positive outlook for biotechnology, citing the sector’s defensive characteristics, favorable technical aspects, and improving fundamentals, such as the number of new product approvals, products in clinical trials and the brisk pace of industry consolidation and licensing transactions.With 2009 officially on the books, it appears an appropriate time to review the sector’s performance along with some of the themes highlighted in our previous articles.Complete Story » seekingalpha.com |